ClinicalTrials.gg
CompletedNCT00504959Updated Mar 4, 2016

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

A Phase 4 interventional study of ranibizumab in Subfoveal Choroidal Neovascularization (CNV) and Secondary to Age-related Macular Degeneration (AMD), sponsored by Novartis. Completed at 36 sites in 10 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-03-04.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
234
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
30th of 124
234 · median 64
Started
2007
with 13 others
Phase 4
33 of 125
none open now
Registered
27th of 125
by date
Lead sponsor
7 of 125
Novartis

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 30th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2007, is one of 33 in phase 4, and was the 27th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN

03

Conditions studied

  • Subfoveal Choroidal Neovascularization (CNV)
  • Secondary to Age-related Macular Degeneration (AMD)

Keywords

  • Age-related macular degeneration (AMD),
  • choroidal neovascularization (CNV),
  • vascular endothelial growth factor (VEGF)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of 12-month treatment period of study CRFB002A2302 (EXCITE) or CRFB002A2303

Exclusion criteria

Exclusion Criteria:

  • Concurrent participation in another clinical trial, i.e. use of other drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    1

    ranibizumab

    Drug: ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Safety assessed by incidence and severity of treatment emergent ocular and non-ocular adverse events over 24 month study period with ranibizumab monthly prn (0.5mg/0.05ml)

Secondary outcomes

  1. Efficacy assessed by mean change in BCVA from Baseline at M 6, 12, 18, and 24. Number of injections with ranibizumab. Safety assessed by AEs and SAEs leading to premature discont. of study drug, vital signs, and ophthalmic exams.

07

Study locations

36 sites
  • Novartis Investigational Site
    Melbourne, Australia
  • Novartis Investigative Site
    Laeken, Belgium
  • Novartis Investigative Site
    Leuven, Belgium
  • Novartis Investigative Site
    Liege, Belgium
  • Novartis Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Bonn, Germany
  • Novartis Investigative Site
    Bremen, Germany
  • Novartis Investigative Site
    Chemnitz, Germany
  • Novartis Investigative Site
    Duesseldorf, Germany
  • Novartis Investigative Site
    Kiel, Germany
  • Novartis Investigative Site
    Koeln, Germany
  • Novartis Investigative Site
    Leipzig, Germany
  • Novartis Investigative Site
    Marburg, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Siegburg, Germany
  • Novartis Investigative Site
    Tubingen, Germany
  • Novartis Investigative Site
    Wuerzburg, Germany
  • Novartis Investigative Site
    Budapest, Hungary
  • Novartis Investigative Site
    Debrecen, Hungary
  • Novartis Investigative Site
    Petach-Tikva, Israel
  • Novartis Investigative Site
    Tel - Hashomer, Israel
  • Novartis Investigative Site
    Tel-Aviv, Israel
  • Novartis Investigative Site
    Amsterdam, Netherlands
  • Novartis Investigative Site
    Nijmegen, Netherlands
  • Novartis Investigative Site
    Coimbra, Portugal
  • Novartis Investigative Site
    Porto, Portugal
  • Novartis Investigative Site
    Alicante, Spain
  • Novartis Investigative Site
    Barcelona, Spain
  • Novartis Investigative Site
    Madrid, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Spain
  • Novartis Investigative Site
    Valencia, Spain
  • Novartis Investigative SIte
    Ankara, Turkey
  • Novartis Investigative Site
    Bristol, United Kingdom
  • Novartis Investigative Site
    Southampton, United Kingdom
  • Novartis Investigative Site
    West Midlands, United Kingdom
  • Novartis Investigative Site
    Wolverhampton, United Kingdom
08

References and documents

Publications

  • Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, Seres A, Gekkieva M, Nieweg A, Pilz S; SECURE Study Group. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):130-9. doi: 10.1016/j.ophtha.2012.07.026. Epub 2012 Sep 25. PubMed 23021093 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2007
First posted
Jul 20, 2007
Start
Jul 2007
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
Mar 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00504959
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Jul 20, 2007
Start date
Jul 2007
Primary completion
Jan 2010
Completion
Jan 2010
Last update
Mar 4, 2016

Study contacts

Novartis
study chair · Board of Hacettepe University , Ankara, turkey
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion